echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > This year, pharmaceutical companies "ice and fire two days"! Collen, Lizhu They made over 1 billion, but the two families lost a lot

    This year, pharmaceutical companies "ice and fire two days"! Collen, Lizhu They made over 1 billion, but the two families lost a lot

    • Last Update: 2018-12-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to statistics, as of December 19, 87 pharmaceutical companies in A-share have published the 2018 performance forecast, of which 65 reported good luck (increased in advance, slightly increased, continued to gain and turned loss), accounting for nearly 75%, and 8 companies with expected net profit exceeding 1 billion yuan are XinHeCheng, xinlitai, Kelun pharmaceutical, Ruikang pharmaceutical, Lizhu group, etc.; while 5 companies with expected loss are Hengkang medical and Shanghai Laishi Or more than 1 billion yuan In the future, the implementation of 4 + 7 volume procurement and national promotion, the consistency evaluation of injection generic drugs, the implementation progress of basic drug policies, policies related to high-value consumables and the reform of medical insurance payment may affect the industry structure Collen, Lizhu Eight pharmaceutical enterprises with estimated net profit of more than 1 billion and estimated net profit of more than 1 billion in 2018 have made outstanding achievements among 65 pharmaceutical enterprises with good results, including XinHeCheng, xinlitai, Kelun pharmaceutical, Ruikang pharmaceutical, Lizhu group, etc., with estimated net profit of more than 1 billion yuan XinHeCheng: the main reason is that the average sales price of the leading products is higher than that of the same period last year, and the net profit in 2017 is 1.704 billion yuan Statistics show that in the first three quarters of this year, new and net profit has reached 2 billion 537 million yuan, an increase of 181.60% over the same period last year In the future, we will vigorously develop 4 major plates, including vitamins, new materials, nutrients and flavors and fragrances Xinlitai: the sales promotion efforts were strengthened, the main products maintained a stable growth, new products gradually increased, the sales of pharmaceutical products continued to maintain a stable growth, and the profit contribution increased Kelun pharmaceutical: The company's infusion product structure continued to be optimized, sales promotion efforts strengthened, direct sales customers increased, gross profit and gross profit increased; Yili CHUANNING's production capacity was released, production was fully achieved, and profits increased; the company continued to vigorously promote the "innovation driven" strategy, and research and development costs increased significantly; the company strengthened sales and new drug promotion efforts, market development and maintenance costs, market management, and academic promotion The cost increases, and the product freight increases; the market financing interest rate rises, and the company's financial expenses increase Ruikang pharmaceutical: in full consideration of the increase of the company's financing amount and the increase of financing cost this year, and based on the assumption that there is no significant change in the market, national policies and other factors, and in line with the principle of seeking truth and stability, it is expected that the company's operation is in good condition and its performance is growing steadily Lizhu group: last year, it transferred 100% equity of its subsidiary Zhuhai Weixing Industrial Co., Ltd., increasing the net profit attributable to shareholders of the listed company by 3.284 billion yuan Excluding non recurring profit and loss, it is expected that the net profit attributable to the company's shareholders deducting non recurring profit and loss realized from the beginning of this year to the end of the next reporting period will increase by 15% - 30% over the same period of last year, mainly due to the stability of main business and the further optimization of capital management Hualan biology: the blood products business has maintained a stable growth The vaccine company's tetravalent influenza virus split vaccine was approved for production and sale in 2018 It is estimated that the net profit attributable to shareholders of Listed Companies in 2018 will change by 0% - 35% compared with the same period of last year Yan'an Bikang: In the pharmaceutical sector, the company's acquisition of Runxiang pharmaceutical and Baichuan pharmaceutical, which are not under the same control, has a significant increase in sales revenue compared with the same period of last year However, due to the low profit margin of pharmaceutical commercial circulation, the company's pharmaceutical sector's profit has increased compared with the same period of last year The company's new energy and new material sectors are operating normally Due to the change of financing environment, the company's financing in 2018 The increase in cost has led to an increase in financial expenses compared with the same period of last year, a decrease in government subsidy received compared with the same period of last year, and a decrease in other income of the company compared with the same period of last year At the end of October this year, Bikang issued a notice that the Chinese abbreviation of the company's securities was changed from "Bikang shares" to "Yan'an Bikang" Yifan medicine: it is mainly due to the large drop in the price of vitamin B5 products since the second quarter of 2018 compared with the same period of last year Among the five pharmaceutical companies with loss or over 1 billion estimated loss in 2018, except Qianshan Pharmaceutical Machinery Co., Ltd., the other four are the first loss, of which the loss of Hengkang Medical Co., Ltd and Shanghai Laishi may exceed 1 billion yuan Hengkang medical: it is estimated that this year it will lose 1 billion to 1.4 billion yuan, a year-on-year decline of - 790.3% ~ - 593.07% In the first three quarters, it will lose 387 million yuan, and its net profit in 2017 will be 203 million yuan   In this regard, Hengkang medical said that the first change in performance was part of the traditional Chinese medicine varieties operated by Sichuan hengkangyuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company Due to the centralized production and new listing at the end of the year, its price is expected to continue to fall after September 30, which is expected to have a negative impact on the performance of the whole year; the second is that the company has successively acquired Siyang hospital, Lankao hospital and Australia PrP company in recent years Due to the supply and demand of domestic capital market and the influence of the freezing of the company's controlling shareholders' shares, the company's financing cost is relatively high, which significantly offsets the overall performance of the above acquisition projects; thirdly, the company's loan for the acquisition of Australian PrP company is equivalent to 1 billion yuan (converted at the exchange rate), the exchange rate of Hong Kong dollar continues to rise this year, resulting in a substantial increase in the aggregate profit and loss, reducing the company's profits; fourthly, the company ' The newly-built Ganxi tumor hospital and Mianyang Aibei hospital have been put into operation successively this year, and the market is being cultivated, and the annual loss has reduced the company's profit The fifth is that the company's acquired Pengxi hospital and Ziyang physical examination hospital have not achieved the expected performance in recent years, and the company plans to withdraw the provision for impairment of goodwill The sixth is that the country has vigorously implemented the reform of the medical system in recent years, with the combination of three guarantees and two vote system In some provinces, drug markup was cancelled and drug prices dropped, which had a certain adverse impact on the company's profits Shanghai Laishi: the company's main business operation is stable Due to the fluctuation of capital market, the company's securities investment has a large loss, which is the main reason for the loss of net profit It is estimated that the net profit attributable to the shareholders of the listed company in 2018 will be significantly reduced year on year, with a loss of 1.212-961 billion yuan On December 7, Shanghai Laishi, the "God of shares" of pharmaceutical enterprises, which had been suspended for nearly 10 months, officially resumed trading, and announced the restructuring plan The company plans to purchase all or part of the GDS shares held by keelford and 100% of the shares of Tiancheng Germany held by the shareholders of Tiancheng Germany in the form of issuing shares The total amount of the plan is about 39.114 billion yuan As of the closing on December 17, the market value has evaporated by more than 50 billion yuan; on the same day, Shanghai Laishi received the restructuring inquiry letter from Shenzhen Stock Exchange, raised 9 questions about the restructuring plan issued on December 7, and asked for a written explanation For the sake of performance, according to incomplete statistics, in recent three months, listed pharmaceutical enterprises have issued 17 equity transfer announcements and 3 transfer announcements related to technology and drug approvals Most of the reasons for transfer are to optimize the industrial layout and activate funds Transfer of Equity: for enterprises, divestiture of non-performing assets can improve the overall performance For example, in recent years, Jinjian pharmaceutical, which has been engaged in the production and operation of large-scale infusion for 18 years, was finally sold at 1 yuan, with a single product At the same time, affected by market fluctuations and industrial policies, it has been in a state of continuous loss in recent years Introduction of strategic investment: in addition to the transfer of equity "throw off the burden", listed pharmaceutical enterprises will also speed up the strategic layout by introducing strategic investment For example, Sinopharm holding Guoda pharmacy Co., Ltd., a wholly-owned subsidiary of Sinopharm, will introduce one strategic investor for capital increase and share expansion After the completion of capital increase, the company's shareholding ratio will be 60% and the strategic investor's shareholding ratio will be 40% According to previous media reports, the retail sector is an important strategic sector in the future, and the introduction of strategic investors is also to make Guoda pharmacy develop better and faster Technology transfer: adjust the product structure and realize it quickly Recently, Haizheng xuantai, a subsidiary of Haizheng pharmaceutical, transferred its US and Chinese serial numbers and related technologies of quetiapine fumarate sustained-release tablets and metformin hydrochloride sustained-release tablets (500mg) to Chongqing encong Medical Management Co., Ltd., with a total transfer price of 67 million yuan and 50 million yuan respectively Haizheng pharmaceutical said that the transfer of drug number conforms to the company's overall product development strategy, which is conducive to adjusting the company's product structure, invigorating the company's assets and further optimizing the asset structure It is estimated that the net profit attributable to the owners of the parent company for the above two transactions is about 40 million yuan Some insiders pointed out that although the transfer of equity, introduction of strategic investment, technology transfer and other ways can improve performance in the short term, the medium and long-term impact remains to be observed Enterprises should improve their management level, management ability and comprehensive profitability in combination with policy orientation and industry development, which is the way of development The five key policies may affect the implementation and national promotion of 4 + 7 volume procurement in the industry pattern, consistency evaluation of injection generic drugs, progress in the implementation of basic drug policies, policies related to high-value consumables and reform of medical insurance payment These five key policies may affect the industry pattern Guojun pharmaceutical analysis pointed out that, at present, how to ensure the implementation measures and effects of quantity in various regions, how to realize the price linkage in non-4 + 7 regions, how to coordinate the quantity if linkage, how to calculate the saved procurement cost, how to transfer the payment to the hospital and so on are the key concerns In terms of consistency evaluation of injection generic drugs, a relatively complete framework has not been formed at present, and the evaluation work has not been carried out on a large scale From the work of CDE, it is expected that the consistency evaluation of injection generic drugs in 2019 is expected to achieve a breakthrough In the aspect of medical insurance payment reform, at present, all provinces have basically completed the listing work of provincial medical insurance bureau, and there may be new breakthroughs in the reform of medical insurance payment in the future Guojun pharmaceutical said that as a highly regulated industry, medicine involves the influence of multiple departments and policies from research and development, production, sales, use and reimbursement, while 2018 is an extraordinary year for the pharmaceutical industry The establishment of the National Health Insurance Bureau has become the biggest variable affecting the industry, which will affect the investment strategy of the pharmaceutical industry for a long time Performance forecast of 87 pharmaceutical enterprises in 2018
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.